

# Marta Batus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7342375/publications.pdf>

Version: 2024-02-01

61  
papers

317  
citations

1306789

7  
h-index

887659

17  
g-index

61  
all docs

61  
docs citations

61  
times ranked

599  
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions. American Journal of Clinical Dermatology, 2013, 14, 179-194.	3.3	89
2	Treatment of advanced squamous cell carcinoma of the lung: a review. Translational Lung Cancer Research, 2015, 4, 524-32.	1.3	74
3	Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Practical Radiation Oncology, 2014, 4, 342-348.	1.1	26
4	Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy. Cancers, 2021, 13, 1426.	1.7	17
5	Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience. Pediatric Blood and Cancer, 2017, 64, e26265.	0.8	14
6	Neutrophil to lymphocyte ratio as predictive of prolonged progression free survival (PFS) and overall survival (OS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with second-line PD-1 immune checkpoint inhibitors.. Journal of Clinical Oncology, 2017, 35, e14530-e14530.	0.8	12
7	Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. American Journal of Hospice and Palliative Medicine, 2016, 33, 374-380.	0.8	10
8	Pulmonary metastasectomy in bone and soft tissue sarcoma with metastasis to the lung. Interactive Cardiovascular and Thoracic Surgery, 2021, 33, 879-884.	0.5	9
9	Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2010, 10, 1589-1599.	1.1	8
10	Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy. Oncotarget, 2017, 8, 58108-58121.	0.8	7
11	Heart dose and coronary artery calcification in patients receiving thoracic irradiation for lung cancer. Journal of Thoracic Disease, 2020, 12, 223-231.	0.6	7
12	Outcomes of brain metastasis in high-grade bone and soft tissue sarcoma: An analysis of clinicopathological characteristics and survival data. Rare Tumors, 2021, 13, 203636132110261.	0.3	6
13	Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients. Annals of Translational Medicine, 2017, 5, 152-152.	0.7	6
14	The clinical utility of next-generation sequencing for bone and soft tissue sarcoma. Acta Oncologica, 2022, 61, 38-44.	0.8	6
15	Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/á~L1 directed immune checkpoint inhibition.. Journal of Immunological Methods, 2021, 490, 112956.	0.6	5
16	IMpower150: Exploratory efficacy analysis in patients (pts) with bulky disease.. Journal of Clinical Oncology, 2020, 38, e21637-e21637.	0.8	4
17	What is the clinical impact of staging and surveillance PETâ€CT scan findings in patients with bone and soft tissue sarcoma?. Journal of Surgical Oncology, 2022, , .	0.8	3
18	Potential predictive value of hepatocyte growth factor (HGF) in advanced non-small cell lung cancer (NSCLC) treated with a platinum doublet and bevacizumab.. Journal of Clinical Oncology, 2014, 32, e22000-e22000.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Clinical benefit of next generation sequencing in soft tissue and bone sarcoma: Rush University Medical Center's experience.. Journal of Clinical Oncology, 2019, 37, e22552-e22552.	0.8	2
20	Does synovial sarcoma grade predict oncologic outcomes, and does a low-grade variant exist?. Journal of Surgical Oncology, 2022, , .	0.8	2
21	Associations between longitudinal pretreatment BMI and neutrophil/lymphocyte ratio(NLR) and progression-free(PFS) and overall survival(OS) in advanced NSCLC patients treated with single agent anti-PD-1/anti-PDL1 monoclonal antibodies(mAbs).. Journal of Clinical Oncology, 2021, 39, e21189-e21189.	0.8	1
22	Association of KRAS mutations detected via liquid biopsy in metastatic non-small cell lung cancer patients with high levels of FDG-PET SUV.. Journal of Clinical Oncology, 2017, 35, e20594-e20594.	0.8	1
23	Association of baseline and longitudinal low neutrophil-lymphocyte ratio (NLR) and high lymphocyte counts (LCs) with progression-free survival (PFS) and overall survival (OS) in real world advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with nivolumab (nivo) or pembrolizumab (pembro).. Journal of Clinical Oncology, 2018, 36, e21020-e21020.	0.8	1
24	Associations between baseline serum biomarker levels and cachexia/precachexia in pretreated non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2019, 37, 3054-3054.	0.8	1
25	Differences in circulating angiogenic biomarkers as prognosticator for outcome in bevacizumab-treated nonsquamous non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2014, 32, 11037-11037.	0.8	1
26	Real-world (rw) clinical outcomes for advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) treated with second line (2L) ramucirumab plus docetaxel (R+D) post frontline (1L) platinum based chemotherapy plus immune checkpoint inhibitors (Pt + ICI).. Journal of Clinical Oncology, 2019, 37, e20727-e20727.	0.8	1
27	Real-world tumor response (rwTR) to ramucirumab plus docetaxel (R+D) post platinum-based (Pt) and immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (aNSCLC) patients (pts).. Journal of Clinical Oncology, 2019, 37, e20725-e20725.	0.8	1
28	The prognostic value of neutrophil-to-lymphocyte ratio in patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, e21675-e21675.	0.8	1
29	Psychosocial distress in patients with driver-mutant lung cancer.. Journal of Clinical Oncology, 2021, 39, e24125-e24125.	0.8	0
30	A Pilot Study To Test the Efficacy of a Combination of Gleevec with Thalidomide in Patients with Idiopathic Primary Myelofibrosis, Myelofibrosis with Myeloid Metaplasia and Myelodysplastic Syndromes Who Present with Myelofibrosis.. Blood, 2006, 108, 4841-4841.	0.6	0
31	Hematopoietic Cell Transplantation - Comorbidity Index (HCT-CI) as a Surrogate Marker for Prediction of Transplant Outcome for Patients (pts) with Multiple Myeloma (MM) Undergoing Autologous Stem Cell Transplantation (ASCT): High HCT-CI Score Predicts for Poor Outcome.. Blood, 2007, 110, 5104-5104.	0.6	0
32	Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): A Comparative Study.. Blood, 2007, 110, 5044-5044.	0.6	0
33	Preoperative survivin, ERCC1, and PTEN expression in stage III non-small cell lung cancer (NSCLC) patients (pts) treated with neoadjuvant and definitive chemoradiation and association with overall survival (OS).. Journal of Clinical Oncology, 2012, 30, 7067-7067.	0.8	0
34	EGFR gene mutation and epithelial to mesenchymal transition (EMT) markers in advanced NSCLC patients treated with erlotinib.. Journal of Clinical Oncology, 2012, 30, e18117-e18117.	0.8	0
35	Thyroid transcription factor 1 (TTF-1) and overall survival in wild type EGFR patients treated with erlotinib.. Journal of Clinical Oncology, 2013, 31, e19113-e19113.	0.8	0
36	Epithelial to mesenchymal markers and clinical outcomes on erlotinib in stage IV non-small cell lung cancer patients.. Journal of Clinical Oncology, 2013, 31, e19117-e19117.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Association of overall survival with weight gain during treatment, initial body mass index (BMI), and glucose intolerance (GI) in advanced non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2014, 32, e19033-e19033.	0.8	0
38	Serial neutrophil to lymphocyte ratios (NLR) in relation to weight change and overall survival in patients (Pts) with metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, e19143-e19143.	0.8	0
39	Association of biomarkers of insulin resistance and inflammation with PET CT SUV values in stage IV non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e20589-e20589.	0.8	0
40	KRAS and P53 mutations and FDG-PET as a measure of glycolytic activity in metastatic non-small cell lung cancer patients.. Journal of Clinical Oncology, 2016, 34, 9086-9086.	0.8	0
41	Two year progression free survival in stage IV NSCLC patients treated with pemetrexed continuation maintenance.. Journal of Clinical Oncology, 2016, 34, e20654-e20654.	0.8	0
42	Association of biomarkers of insulin resistance and inflammation with skeletal muscle index (SMI) in stage IV non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 10013-10013.	0.8	0
43	Association of acute phase proteins with a serum proteomic test in previously treated patients with NSCLC.. Journal of Clinical Oncology, 2016, 34, e20649-e20649.	0.8	0
44	Circulating biomarkers and outcomes in advanced non-small cell lung cancer patients treated with anti-PD1 (program death 1 receptor) monoclonal antibodies.. Journal of Clinical Oncology, 2017, 35, e20592-e20592.	0.8	0
45	Mature progression-free survival (PFS) milestones in real world stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) +/- bevacizumab(Bev) followed by pem +/-bev maintenance.. Journal of Clinical Oncology, 2018, 36, e21063-e21063.	0.8	0
46	Ramucirumab (ram), immune checkpoint inhibitors (ICIs), and single-agent chemotherapy (chemo) usage in real-world advanced non-small cell lung cancer (aNSCLC) patients (pts) after rapid disease progression (RDP) on platinum (Pt).. Journal of Clinical Oncology, 2018, 36, e21162-e21162.	0.8	0
47	Sequencing of ramucirumab (ram) and immune checkpoint inhibitors (ICIs) in platinum (Pt)-treated real-world patients (pts) with advanced non-small cell lung cancer (aNSCLC).. Journal of Clinical Oncology, 2018, 36, e21209-e21209.	0.8	0
48	Prognostic value of neutrophil-to-lymphocyte ratio (NLR), serum albumin and sequence of immunotherapy (Immuno.) on overall survival (OS), and progression free survival (PFS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with ramucirumab plus docetaxel (RD).. Journal of Clinical Oncology, 2018, 36, e21163-e21163.	0.8	0
49	Real-world economic burden of rapid disease progression (RDP) in patients (pts) with advanced/metastatic non-small cell lung cancer (aNSCLC).. Journal of Clinical Oncology, 2019, 37, e20716-e20716.	0.8	0
50	Treatment of soft tissue sarcoma with a novel cold plasma jet.. Journal of Clinical Oncology, 2019, 37, e22562-e22562.	0.8	0
51	Real-world clinical burden of aggressive disease (AD) in advanced/metastatic non small cell lung cancer (aNSCLC).. Journal of Clinical Oncology, 2019, 37, e20723-e20723.	0.8	0
52	Correlating the effects of VeriStrat result, anti-PD1 therapy, and neutrophil-to-lymphocyte ratio (NLR) on progression-free survival (PFS) in patients with stage IV non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, e20660-e20660.	0.8	0
53	Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP).. Journal of Clinical Oncology, 2019, 37, e20706-e20706.	0.8	0
54	Decreasing BMI/weight immediately prior to starting anti-PD-1/PDL-1 monoclonal antibodies for treatment for stage IV non-small cell lung cancer is associated with shorter progression-free survival.. Journal of Clinical Oncology, 2019, 37, e20710-e20710.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Mature, real world progression-free survival (PFS) and overall survival (OS) milestones in stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) followed by pem+/-bevacizumab(Bev) maintenance.. Journal of Clinical Oncology, 2019, 37, e20721-e20721.	0.8	0
56	Changes in skeletal muscle mass during PD-1 and PD-L1 checkpoint inhibitor therapy in advanced-stage non-small cell lung cancer patients.. Journal of Clinical Oncology, 2019, 37, e14061-e14061.	0.8	0
57	RNA pathway enrichment in serum-based mass spectroscopy prognostic analyses.. Journal of Clinical Oncology, 2020, 38, e15197-e15197.	0.8	0
58	PET-CT staging affects time to treatment in sarcoma. Surgical Oncology, 2022, 41, 101732.	0.8	0
59	Gender and weight change, skeletal muscle index(SMI) change, and survival in advanced non-small cell lung cancer(NSCLC) patients(pts.) receiving platinum chemotherapy.. Journal of Clinical Oncology, 2022, 40, e24080-e24080.	0.8	0
60	NRG-DT001 phase Ib trial of neoadjuvant navtemadlin (previously AMG232 and KRT232) concurrent with preoperative radiotherapy in wild-type p53 soft tissue sarcoma of the extremity and body wall.. Journal of Clinical Oncology, 2022, 40, 11521-11521.	0.8	0
61	Clinical and laboratory parameters associated with rapid progression in advanced NSCLC patients treated with second or third-line single agent immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2022, 40, e21087-e21087.	0.8	0